by | May 27, 2024 | Publications
Cureus. 2024 Apr 26;16(4):e59056. doi: 10.7759/cureus.59056. eCollection 2024 Apr. ABSTRACT Multiple myeloma (MM) is a plasma cell malignancy belonging to the class of monoclonal gammopathies that leads to end-organ damage myeloma events that encompass anemia, the...
by | May 27, 2024 | Publications
Front Oncol. 2024 May 10;14:1398902. doi: 10.3389/fonc.2024.1398902. eCollection 2024. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration...
by | May 27, 2024 | Publications
Front Oncol. 2024 May 10;14:1357996. doi: 10.3389/fonc.2024.1357996. eCollection 2024. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells in bone marrow. Upfront identification of...
by | May 27, 2024 | Publications
J Oral Maxillofac Pathol. 2024 Jan-Mar;28(1):138-141. doi: 10.4103/jomfp.jomfp_297_23. Epub 2024 Apr 15. ABSTRACT Multiple myeloma (MM) is a plasma cell malignancy, and its typical radiographic presentation includes punched-out radiolucency of the skull. It is a...
by | May 27, 2024 | Publications
Lancet Haematol. 2024 May 23:S2352-3026(24)00105-4. doi: 10.1016/S2352-3026(24)00105-4. Online ahead of print. ABSTRACT BACKGROUND: Currently, the use of radiotherapy alone for people with multiple myeloma is limited to palliation of pain, pending fracture, and...
by | May 26, 2024 | Publications
Eur J Oncol Nurs. 2024 May 3;70:102604. doi: 10.1016/j.ejon.2024.102604. Online ahead of print. ABSTRACT PURPOSE: The aim of this study was to understand and explore the caregiving experience of adult children of patients with multiple myeloma (MM) during diagnosis...
